Download PDF
Nuklearmedizin 2024; 63(03): 224-226
DOI: 10.1055/a-2224-9536
Case Report

Dosimetry in a patient with peritoneal dialysis treated with [177Lu]Lu-PSMA-617

Dosimetrie bei einem Peritonealdialysepatienten mit [177Lu]Lu-PSMA-617 Therapie
Kathrin Glass
1   Department of Nuclear Medicine, University Hospital Halle, Halle, Germany (Ringgold ID: RIN14942)
,
Andreas Hendrik Hering
2   Ambulatory Healthcare Center Nuclear Medicine and Hybrid Imaging Saalekreis, Merseburg, Germany
,
Alexander Heinzel
1   Department of Nuclear Medicine, University Hospital Halle, Halle, Germany (Ringgold ID: RIN14942)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Introduction

Based on the phase III Vision trial [177Lu]Lu-PSMA-617 has been approved for patients with advanced castration resistant prostate cancer. However, the optimal dose and how to adjust this dose to the special needs of individual patients remains an open question [1]. This is of particular importance in patients with end-stage renal disease. As the radioligand is subject to renal excretion, decrease of excretion could consecutively lead to higher doses in tumour and healthy organs. It remains unclear how to determine the exact dose for such patients. Here we report the clinical case of a patient with end-stage renal disease who received continuous ambulatory peritoneal dialysis (CAPD) and was presented for treatment with [177Lu]Lu-PSMA-617.



Publication History

Received: 03 August 2023

Accepted after revision: 07 December 2023

Article published online:
08 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literature

  • 1 Kaptein EM, Levenson H, Siegel ME. et al. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 2000; 85 (09) 3058-3064
    PubMedSearch in Google Scholar
  • 2 Rosar F, Wenner F, Khreish F. et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 2022; 49 (05) 1584-1594
    CrossrefPubMedSearch in Google Scholar
  • 3 Alsadi A DM, Bouhali O, O’Doherty J. Towards routine clinical use of dosimetry in [177Lu]Lu-PSMA prostate cancer radionuclide therapy: current effort and future prospectives.. Frontiers in Physics 2022; 10
    CrossrefSearch in Google Scholar
  • 4 de Bakker M, Dominicus N, Meeuwis A. et al. Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging 2023; 50 (12) 3572-3575
    CrossrefPubMedSearch in Google Scholar
  • 5 Teitelbaum I. Peritoneal Dialysis. N Engl J Med 2021; 385 (19) 1786-1795
    CrossrefPubMedSearch in Google Scholar